Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report

A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week benralizumab dosing interval, discussion arose as to whether benralizumab should be administered or if treatment should be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroes, Johannes Anthon, Zielhuis, Sander Wilhelm, Bethlehem, Carina, Ten Brinke, Anneke, Van Roon, Eric Nico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251165/
https://www.ncbi.nlm.nih.gov/pubmed/33883206
http://dx.doi.org/10.1136/ejhpharm-2020-002660
_version_ 1784739977573171200
author Kroes, Johannes Anthon
Zielhuis, Sander Wilhelm
Bethlehem, Carina
Ten Brinke, Anneke
Van Roon, Eric Nico
author_facet Kroes, Johannes Anthon
Zielhuis, Sander Wilhelm
Bethlehem, Carina
Ten Brinke, Anneke
Van Roon, Eric Nico
author_sort Kroes, Johannes Anthon
collection PubMed
description A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week benralizumab dosing interval, discussion arose as to whether benralizumab should be administered or if treatment should be discontinued, due to the lack of experience with benralizumab in this situation. Severe broncho-obstruction developed, and the next injection of benralizumab was administered during ICU admission without detrimental symptoms. With this case report, we would like to share our experience with the safe administration of benralizumab during COVID-19 pneumonia, guiding doctors in future decision making.
format Online
Article
Text
id pubmed-9251165
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-92511652022-07-05 Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report Kroes, Johannes Anthon Zielhuis, Sander Wilhelm Bethlehem, Carina Ten Brinke, Anneke Van Roon, Eric Nico Eur J Hosp Pharm Case Report A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week benralizumab dosing interval, discussion arose as to whether benralizumab should be administered or if treatment should be discontinued, due to the lack of experience with benralizumab in this situation. Severe broncho-obstruction developed, and the next injection of benralizumab was administered during ICU admission without detrimental symptoms. With this case report, we would like to share our experience with the safe administration of benralizumab during COVID-19 pneumonia, guiding doctors in future decision making. BMJ Publishing Group 2022-07 2021-04-21 /pmc/articles/PMC9251165/ /pubmed/33883206 http://dx.doi.org/10.1136/ejhpharm-2020-002660 Text en © European Association of Hospital Pharmacists 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Case Report
Kroes, Johannes Anthon
Zielhuis, Sander Wilhelm
Bethlehem, Carina
Ten Brinke, Anneke
Van Roon, Eric Nico
Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
title Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
title_full Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
title_fullStr Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
title_full_unstemmed Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
title_short Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
title_sort administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with covid-19 pneumonia: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251165/
https://www.ncbi.nlm.nih.gov/pubmed/33883206
http://dx.doi.org/10.1136/ejhpharm-2020-002660
work_keys_str_mv AT kroesjohannesanthon administrationofbenralizumabinapatientwithsevereasthmaadmittedtotheintensivecareunitwithcovid19pneumoniacasereport
AT zielhuissanderwilhelm administrationofbenralizumabinapatientwithsevereasthmaadmittedtotheintensivecareunitwithcovid19pneumoniacasereport
AT bethlehemcarina administrationofbenralizumabinapatientwithsevereasthmaadmittedtotheintensivecareunitwithcovid19pneumoniacasereport
AT tenbrinkeanneke administrationofbenralizumabinapatientwithsevereasthmaadmittedtotheintensivecareunitwithcovid19pneumoniacasereport
AT vanroonericnico administrationofbenralizumabinapatientwithsevereasthmaadmittedtotheintensivecareunitwithcovid19pneumoniacasereport

Ejemplares similares